NasdaqGM:KODBiotechs
A Look At Kodiak Sciences (KOD) Valuation After Positive GLOW2 Phase III Zenkuda Results
Why Kodiak Sciences Stock Is Back in Focus After GLOW2 Results
Kodiak Sciences (KOD) is drawing fresh attention after reporting positive top line Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, which has prompted accelerated regulatory plans and renewed interest in its ophthalmology pipeline.
See our latest analysis for Kodiak Sciences.
The GLOW2 data initially helped extend Kodiak Sciences’ strong multi year run, with the 1 year total shareholder return now very large relative to the...